Disease modifying antirheumatic drug (DMARD) use
| Finland | Sweden | United Kingdom | The Netherlands | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| %2-150 | Efficacy2-151 | % | Efficacy | % | Efficacy | % | Efficacy | ||||||
| 12% Low | 39% Low | 1% Low | 16% Low | ||||||||||
| 100 | 44% Moderate | 67 | 40% Moderate | 652-152 | 28% Moderate | 94 | 25% Moderate | ||||||
| 40% High | 17% High | 69% High | 58% High | ||||||||||
| 4% Not specified | 4% Not specified | 2% Not specified | 1% Not specified | ||||||||||
↵2-150 Percentage of patients using at least one DMARD during the five year follow up period.
↵2-151 DMARDs used, classified according to the attributed efficacy: low = chloroquine, oral gold, or a combination; moderate = azathioprine,d-penicillamine, intramuscular gold, or a combination; high = methotrexate, sulfasalazine, or a combination; not specified = incidentially (that is, <5%) prescribed DMARDs.
↵2-152 Estimated percentage of patients using at least one DMARD during the five year follow up period.